Podcasts about guidelines

Revisiting EPA climate guidelines, debating Sharia on Capitol Hill, and Petra returns with a new album. Plus, Hunter Baker on sports gambling, a slip-and-fall lawyer as Olympic curling alternate, and the Thursday morning newsSupport The World and Everything in It today at wng.org/donateAdditional support comes from The Master's University, equipping students for lives of faithfulness to The Master, Jesus Christ. masters.eduFrom The Joshua Program at St. Dunstan's Academy in the Blue Ridge Mountains: work, prayer, and adventure for young men. stdunstansacademy.org

Meg, Hal and Symphony discuss episode 199 of Welcome to Night Vale: Guidelines for Retrieval. They chat about hope, trauma and frozen yogurt toppings. They are joined by Night Vale writer Brie Williams for a conversation about the funniest thing you can put in an eye patch, a go to diner order, recurring nightmares and how life experiences inspired this episode.  Find out more about calzones on our ⁠⁠⁠⁠⁠Patreon.⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠www.patreon.com/goodmorningnightvale⁠⁠⁠⁠⁠ Follow us on ⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠. Good Morning Night Vale is a production of ⁠⁠⁠⁠⁠Night Vale Presents⁠⁠⁠⁠⁠ Hosted by Symphony Sanders, Hal Lublin, and Meg Bashwiner Produced by Meg Bashwiner Edited by Felicia Dominguez Mixed by Vincent Cacchione Theme Music by ⁠⁠⁠⁠⁠Disparition Learn more about your ad choices. Visit megaphone.fm/adchoices

PSR Podcast is a listener supported outreach of Be Broken Ministries. Partner with us through giving at BeBroken.org/donate. Thank you for your support!----------In this episode, I chat with Elizabeth Urbanowicz about her book, Helping Your Kids Know God's Good Design: 40 Questions and Answers on Sexuality and Gender. Elizabeth shares her journey as a Christian educator and how she equips parents to teach kids about sexuality and gender from a biblical perspective.We discuss God's design for sex, the importance of ongoing conversations, how to address tough topics like pornography and gender confusion, and how to love others with grace and truth. Elizabeth offers practical advice for parents navigating today's culture, always pointing back to the sufficiency of God's Word and a thriving relationship with Jesus.To learn more about Elizabeth and get her book, visit FoundationWorldview.com.Topics Covered in this Episode:Biblical design for sexuality and marriage as a lifelong covenant between one man and one woman.Understanding sex as a gift within marriage for intimacy and procreation.Importance of focusing on the relationship with Christ rather than idolizing marriage.Strategies for parents to educate children about sexuality and gender in a culturally saturated environment.Addressing the topic of pornography and preparing children for potential exposure.The significance of teaching children about God's design for sex from a young age.Navigating conversations about sexual brokenness and honesty with children.Teaching children to love others while maintaining biblical truth without affirming sin.Guidelines for media consumption and discernment regarding content.Encouraging ongoing growth and reliance on God's grace in discussions about sexuality.More Resources:Helping Your Kids Know God's Good Design by Elizabeth UrbanowiczFamily Integrity: Curiosity (online course)7 Tips to Help You Address Sexual Issues with Your KidsRelated Podcasts:Parenting in a Hyper-Sexualized and Identity-Confused CultureNavigating Identity and Sexuality: A Compassionate Approach for ParentsHow Parents Can Effectively Engage in Sexual Discipleship with their Kids----------Please rate and review our podcast: Apple PodcastsFollow us on our Vimeo Channel.

The new 2025-2030 Dietary Guidelines for Americans were released on January 7, 2026 and already they have created quite a stir. Perhaps you've seen the Guidelines and wonder what to make of them too. For one, there's a featured image of an inverted pyramid comprising foods like butter, steak, whole milk and cheese. Then when you get onto the realfood.gov website, you are immediately shown three images - a stalk of broccoli, a carton of whole milk, and a piece of steak. But are all foods healthy and good for long-term health as long they don't come processed and from a factory?   This is definitely worth discussing. So in this episode, let's take a closer look at these Guidelines recently released. In this first part, I'll highlight the positive recommendations made within the Guidelines and then 2 important things you need to know about them. I hope you'll walk away with greater clarity into the matter and be more informed and equipped to make the best food choices for your health. Ready? Grab a warm cup of tea and let's get started!     For the list of references to this episode, please go to the episode webpage at: www.plantnourished.com/blog     Contact -> healthnow@plantnourished.com Learn -> www.plantnourished.com Join -> Plant-Powered Life Transformation Course: www.plantnourished.com/ppltcourse Get Free 15-Minute Strategy Call -> www.plantnourished.com/strategycall Free Resource -> 7 Ways to Test-Drive a Plant-Based Diet: www.plantnourished.com/testdrive     Have a question about plant-based diets that you would like answered on the Plant Based Eating Made Easy Podcast? Send it by email (healthnow@plantnourished.com) or submit it by a voice message here: www.speakpipe.com/plantnourished

In this episode of "PICU Doc on Call," Drs. Pradip Kamat and Rahul Damania dive into a pediatric ICU case involving a 4-year-old girl who presents with severe anemia and bleeding, ultimately diagnosed with von Willebrand disease (VWD). They chat about the causes and different types of VWD, walk through the key clinical features, and break down how to diagnose and manage this condition. Drs. Kamat and Damania highlight the important roles of desmopressin and factor concentrates in treatment. Throughout the episode, they stress the need to recognize VWD in kids who have mucosal bleeding and offer practical tips for intensivists on lab evaluation and treatment strategies for this common inherited bleeding disorder.Show Nighlights: Clinical case discussion of a 4-year-old girl with severe anemia and bleeding symptomsDiagnosis of von Willebrand disease (VWD) and its significance in pediatric critical careEtiology and pathogenesis of von Willebrand diseaseClassification of von Willebrand disease into types (Type 1, Type 2 with subtypes, Type 3)Clinical manifestations and symptoms associated with VWDDiagnostic approach for identifying von Willebrand disease, including laboratory testsManagement strategies for VWD, including desmopressin and von Willebrand factor concentratesRole of adjunctive therapies such as antifibrinolytics and hormonal treatmentsImportance of multidisciplinary collaboration in managing complex bleeding disordersOverview of the pathophysiology of von Willebrand factor and its role in hemostasisReferences:Fuhrman & Zimmerman - Textbook of Pediatric Critical Care Chapter ***.Reference 1: Leebeek FW, Eikenboom JC. Von Willebrand's Disease. N Engl J Med. 2016 Nov 24;375(21):2067-2080.Reference 2: Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015 Mar 26;125(13):2029-37.Platton S, Baker P, Bowyer A, et al. Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors' Organisation and the British Society for Hematology. Br J Haematol 2024 May;204(5):1714-1731.Mohinani A, Patel S, Tan V, Kartika T, Olson S, DeLoughery TG, Shatzel J. Desmopressin as a hemostatic and blood-sparing agent in bleeding disorders. Eur J Haematol. 2023 May;110(5):470-479. doi: 10.1111/ejh.13930. Epub 2023 Feb 12. PMID: 36656570; PMCID: PMC10073345.

Send us a textIn this episode...Bottlesharing and Amaro-Inspired StoutsDropping By Frog Rock BrewingWholesalers vs. Brewers Association TakesSurprising 2025 N/A Beer InsightsGenerational Booze Stats2026 Edition of Beer Style Guidelines OutPolitical Beer Drama in Wisconsin150-Year Old Beer Found in ArizonaBear Poop Beer For The Super BowlThanks for listening to Beer Guys Radio! Your hosts are Tim Dennis and Brian Hewitt with producer Nate "Mo' Mic Nate" Ellingson and occasional appearances from Becky Smalls.Subscribe to Beer Guys Radio on your favorite app: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSSFollow Beer Guys Radio: Facebook | Instagram | Twitter | YouTube If you enjoy the show we'd appreciate your support on Patreon. Patrons get cool perks like early, commercial-free episodes, swag, access to our exclusive Discord server, and more!

In this episode, Eric Hörst and nutrition science graduate student Jonathan Hörst discuss the newly updated U.S. dietary guidance and the concept of a "flipped" or re-prioritized food pyramid that emphasizes nutrient density, whole foods, and protein—rather than carbohydrate-heavy intake patterns of past guidelines. Drawing from current nutrition science and academic discussion at the University of Utah, they explore both the strengths of the update and the practical challenges of applying it. Key takeaways for climbers and athletes include prioritizing adequate protein, limiting ultra-processed foods, choosing whole-food carbohydrate sources, and matching carbohydrate intake to activity level. The episode concludes by emphasizing individualized nutrition, performance context, and consistency over perfection. Jonathan also provides some breakfast and dinner tips for climbers looking to optimize energy availability, performance, and recovery. RUNDOWN 0:30 - Intro to New Food Pyramid 1:00 - About today's expert, Jonathan Hörst, from Department of Nutritional Science at the University of Utah. 2:20 - Seismic changes to the USDA food guideline for Americans 6:00 - Guidelines catching up to modern nutritional science 9:35 - Inverting the old food pyramid 11:40 - 6 major changes to the nutritional guidelines for health and disease prevention 12:00 - #1 Prioritize protein 16:15 - #2: Added Sugar Gets a Hard Line 19:15 - #3: Whole Grains Yes — Refined Carbs No Brief Podcast Sponsor message from PhysiVantage Nutrition. Save 15% off full-price nutrition with checkout code: PODCAST15 at PhysiVantage.com (USA and Canada only). European climbers, please get your PhysiVantage from the  EPIC-TV Shop or Oliunid.com. Mexiocan climbers visit PhysiVantage.mx 21:35 - #4: Lower-Carbohydrate Diets Are Acknowledged 25:35 - #5: Ultra-Processed Foods Are Explicitly Called Out 31:50 - #6: A More Nuanced Approach to Fat Intake 37:30 - Key takeaways & actionable items for climbers 40:00 - Examples of healthy, effective fueling at breakfast and dinner 47:00 - Jonathan's current training and climbing goals 49:40 - Contact Jonathan vis DM on Instagram: @jonathan_horst 49:55 - PLEASE write a 5-star review on Apple Podcasts and SHARE this podcast with a friend! 50:30 - Hörst out! A word from this podcast's sponsor, PhysiVantage. Get 15% off full-priced nutrition with checkout code: PODCAST15 (North America only). Europe and elsewhere visit EPIC-TV Shop or BananaFingers.com to get your PhysiVantage! SAVE on La Sportiva shoes here >> Thank you! La Sportiva, Maxim Ropes, DMM Climbing, Friction Labs Music by Misty Murphy Follow Eric on Twitter @Train4Climbing Check out Eric's YouTube channel. Follow Eric on Facebook! And on Instagram at: Training4Climbing Copyright 2026 Eric Hörst | Horst Training, LLC.

In this episode of the Brain & Life Podcast, host Dr. Daniel Correa is joined by Dr. Emmanuelle Waubant, professor of neurology at UCSF and Director of the UCSF Regional Pediatric Multiple Sclerosis Center. Together, they explore how diet, microbiome, and environmental factors influence the progression of multiple sclerosis, with a special focus on pediatric cases. Dr. Waubant also discusses the role of dietary patterns and vitamin D and highlights how emotional well-being and physical activity can impact disease outcomes.   Additional Resources Expert Insights and Practical Tips for Managing Multiple Sclerosis How Ultra-processed Foods Can Have a Negative Effect on Brain Health Nutrition for kids: Guidelines for a healthy diet   Brain & Life Podcast Episodes on These Topics Advocating for a Multiple Sclerosis Diagnosis with Comedian Kellye Howard Embracing Each Day with Author and MS Advocate Lilibet Snellings Kyte Voices from the Multiple Sclerosis Community   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media Guests: Dr. Emmanuelle Waubant @ucsfmedicine Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

Opening Bible Verse: Galatians 5: This year we are doing my group coaching course together via this podcast! It's free and it only gets better as the year progresses.  In January we are working on building the habit of a morning prayer routine. I highly recommend the rosary. It's only about 20 minutes and you'll meditate on the whole life of Jesus with each passing mystery. Before moving on to decluttering in February, get your morning prayer routine going. This program builds on itself and you'll need a strong foundation of faith if you are going to succeed this year. If you're new, give this first episode of 2026 a listen to hear where to begin: 316. Your 2026 Life Overhaul Plan: Faith, Clutter, Debt, Diet and More!   If you've never prayed a rosary or you want to see how you can incorporate it into active decluttering, here is the first episode of my rosary declutter series from last summer. 288. Summer Declutter Series Week ***Are you so overwhelmed with clutter that you find yourself unable to make any decisions? Do you plan on decluttering only to find yourself standing in a room confused about where to start? Are you hoping motivation will strike and you'll get it all done in one weekend? If this sounds like you, let's work together.   Book a one hour virtual coaching session via Zoom. Together we craft a decluttering plan and I walk you through the process. You'll complete much of the decluttering on your own time at your own pace. I just give you the roadmap and the accountability. Cost $77 per hour. Virtual Coaching Schedule   Not sure what you need? No problem! Book a complimentary 15 minute clarity call. We'll meet via Zoom and see if working with me would benefit you.  Email me at: tightshipmama@gmail.com to schedule a time.   Looking for community of like-minded women? Join the private Facebook community here: Facebook Group   Prefer to receive a weekly email with the monthly freebie like a group rosary, group declutter, or budget Q&As?  Join my mailing list here: Monthly Newsletter   Do you like to watch a podcast? Check out my YouTube channel here:  YouTube    For any other inquiries or guest appearances, please email me at: tightshipmama@gmail.com    

What if the most powerful cancer treatments already exist — but aren't being offered because they fall outside the guidelines?In this episode of Integrative Cancer Solutions, Dr. Michael Karlfeldt sits down with world-renowned interventional radiologist and oncology innovator Dr. Syed Hasnain Haider-Shah to explore why modern cancer care often prioritizes protocols over patients. From catheter-directed chemotherapy and tumor embolization to immune-based strategies, photobiomodulation, and precision nutrition, Dr. Shah reveals how advanced cancer treatments are being used globally — especially in China — while remaining largely inaccessible in the U.S.This conversation dives deep into the limitations of chemotherapy and radiation, the intelligence of cancer stem cells, immune system suppression, cancer cachexia, and why integrative, individualized approaches give patients their best chance at long-term survival. If you or someone you love is navigating a cancer diagnosis and searching for real options beyond “standard of care,” this episode is essential listening.Key Takeaways:5:20 Radiation therapy risks and how to support recovery nutritionally11:46 Why systemic chemotherapy often fails and selects for aggressive cancer cells12:17 Catheter-directed chemotherapy: targeting tumors without poisoning the body16:25 The immune system as the most powerful anti-cancer weapon26:37 Tumor embolization: starving cancer by cutting off its blood supply34:50 Why advanced cancer therapies thrive in China but are restricted in the U.S.Resources Mentioned:Williams Cancer Institute (Mexico) – https://williamscancerinstitute.comPhotobiomodulation / Intravenous Light Therapy (General Overview) – https://pubmed.ncbi.nlm.nih.gov Want to guest on our shows?Calendly Link for Integrative Lyme Solutions: https://calendly.com/drmichaelk/integrative-lyme-solutions-podcast-interviewCalendly Link for Integrative Cancer Solutions: https://calendly.com/drmichaelk/podcast-interviewCalendly Link for Dr. K Show: https://calendly.com/drmichaelk/dr-k-show-interview Breaking Free From Lyme: A Comprehensive Guide to Healing and Recovery-URL: https://store.thekarlfeldtcenter.com/products/breaking-free-from-lyme-Price: $24.99-Discount Code: LYMEPODCASTUnleashing 10X Power: A Revolutionary Approach to Conquering Cancer-URL: https://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancer-URL: https://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-Discount Code: CANCERPODCAST2The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and Purpose-URL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-Discount Code: DRKSHOWPODCAST -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1 Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Send us a textIn 1992, a room full of weight loss experts admitted diets don't work and that weight regain is almost inevitable within five years. Then they recommended diets anyway. Fast forward to 2025, and the UK's NICE guidelines acknowledge weight cycling causes harm, that the evidence is overwhelmingly poor quality, and that people will likely regain the weight. Yet they still recommend 800-calorie diets, even for people with eating disorders. In this episode, I expose how medical guidelines have become a masterclass in institutional lying—where committees acknowledge the evidence shows diets fail, cause harm, and offer no long-term benefit, yet recommend them regardless. Because the industry's already doing it, the government's already funding it, and admitting the truth would be too expensive. This isn't medicine. This is willful harm dressed up in clinical language, and the people writing these guidelines need to be held accountable. Got a question for the next podcast? Let me know! Connect With Me WEEKLY NEWSLETTER: Get a free script when you sign up THE WEIGHTING ROOM: A community where authenticity thrives and every voice matters The CONSULTING ROOM: Get answers to all your medical questions via DM or Voice Note PLUS access to my entire library of paid resources CONSULTATION: For the ultimate transformation in your healthcare journe THE WEIGH FORWARD: For people who are being denied surgery because of their weight FREE GUIDES:Evidence-based, not diet nonsense Find me on Instagram, YouTube, and LinkedIn.

In this episode of JHLT: The Podcast, the Digital Media Editors host a discussion on a new consensus statement from ISHLT on Short Telomere Syndrome (STS) and Lung Transplantation. The document was first published last month. They're joined by document leads Andrew Courtwright, MD, PhD, of the University of Pennsylvania in Philadelphia; Dr. John Mackintosh of Prince Charles Hospital in Brisbane; and John McDyer, MD, of the University of Pittsburgh Medical Center in Pittsburgh. The conversation includes discussion of: Recommendations for assessing patients for STS Which patients we should screen How the diagnosis influences transplant decision making and risk assessment How STS impacts immunosuppression Extrapulmonary comorbidities Future areas for research ISHLT Standards, Guidelines, and Consensus Statements are open to all at ISHLT.org. For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Return later this month for a conversation on barriers and opportunities in utilizing DCD hearts in transplantation. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: All educational content in this podcast was developed as part of the Circulation Health collaborative working project between Boehringer Ingelheim Limited, Greater Manchester Primary Care Provider Board and Health Innovation Manchester. Content has been created by Circulation Health Clinical Leads for educational purposes, reflecting NHS Clinical Lead and guideline-based recommendations. Boehringer Ingelheim had no input into content development. They have provided financial resources to support Podcast recordings related to this project. Darren would like us to make you all aware that he has working relationships with pharmaceutical industry partners. Specifically, that he has received speak fees and consultancy fees from AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Bayer, and Lilly, and has been part of collaborative working agreements with Novartis, Boehringer Ingelheim, and AstraZeneca. You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down new research on liver transplantation, hepatocellular carcinoma (HCC), and the ongoing evolution of surveillance strategies in chronic liver disease. Drawing on their extensive experience as transplant hepatologists, Brown and Reau place new data into practical context, highlighting where evidence may meaningfully inform practice and where unanswered questions remain.Key episode timestamps:0:00:00 – Introduction0:00:19 – Frailty & Transplant Evaluation0:02:54 – How Centers Use Frailty Measures0:04:37 – Practicalities of the Six‑Minute Walk0:06:10 – MELD 3.0 and Sex/Size Disparities0:08:42 – Exception Points & Size Constraints0:10:05 – Need for a Dynamic MELD System0:10:19 – Immunotherapy as Bridge/Downstaging for HCC0:13:34 – Real‑World Use of IO Around Transplant0:15:22 – Managing Rejection Risk0:19:03 – MASLD Population & Surveillance Gaps0:20:21 – Adherence to HCC Surveillance0:22:42 – Practical Barriers: AFP, Ultrasound, Radiology Reports0:24:02 – Shift Toward Blood-Based Surveillance0:26:01 – How AFP-L3 and DCP Are Used in Practice0:27:39 – Rising AFP, Imaging Strategy & Broader Trend to Blood Tests0:28:27 – Guidelines vs Real-World Practice0:29:37 – Closing Thoughts on Guidelines & Early Detection

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest recommendations on first-line and subsequent therapeutic options. Dr. Reuss emphasizes the need for shared decision-making between clinicians and patients. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02825    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It is great to have you back on the show today, Dr. Reuss. Dr. Joshua Reuss: Happy to be here, Brittany. Brittany Harvey: Just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is updated on an ongoing basis. So, what prompted this latest update to the recommendations? Dr. Joshua Reuss: Our committee is tasked with making routine updates to the living guidelines and really keeping them living, right? So, evaluating new data as it is coming in to see, is this practice changing? Is this data that should inform and potentially alter our guideline recommendations so that practitioners and other care providers could really make the best treatment decisions for their patients? So that is something that happens on a more routine basis, but periodically, we are tasked with performing a more comprehensive update of our guideline where we really evaluate every one of our point recommendations, the data associated with these recommendations, to be sure that these are up to date, these are comprehensive, and to see if we need to alter anything in the language of these updates. Brittany Harvey: Excellent. Thank you for providing that background. And yes, this is truly a comprehensive update that goes through all the latest literature. Given that, I would like to review what has changed and what is new in the recommendations. So, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: So there are two main guidelines that we recommend from this panel. One is a driver mutation-positive guideline and the other is a driver mutation-negative guideline. And I think on first blush, one might look at kind of the recent flurry of approvals and new data and say, well, all the excitement, you know, is in the driver mutation-positive guideline. But I would say that the driver mutation-negative guideline is equally as important and really has several unique challenges associated with it. You know, first and foremost is that there are really a multitude of regimens that can be considered for any one patient. And how to choose between one can be quite difficult and a stressful challenge that clinicians can have, particularly since there are really no randomized studies comparing these regimens in a head-to-head fashion. In addition, you know, these guidelines are really broken down by two key factors. One is disease histology, so namely squamous versus non-squamous histology. And the other is PD-L1 status, broken down into one of three tertiles: PD-L1 high, which is greater than or equal to 50% expression; PD-L1 low, which is 1% to 49% expression; and then PD-L1 negative or unknown. So what you are really looking at, if you do that math, is really six unique patient subpopulations where we need to make a recommendation on one of the multitude of treatment regimens that is approved. And what that means is you are oftentimes really looking at subset and sub-subset level data to help inform clinicians in their treatment decision making, which can be quite challenging because as those small subsets of data is more and more parsed, there are many confounders that can be interjected there. And so I think the committee is tasked with really quite a challenge in terms of how to really communicate and broadcast that data in a way that informs clinicians in making a decision on what is the right treatment for their patient. Brittany Harvey: Absolutely. It can be challenging to interpret that subgroup data across several different studies that are reporting on different regimens and different outcomes. And I appreciate you mentioning the driver mutation-positive guideline as well. Listeners can check out the companion episode with Dr. Puri for more information on what is changed in the driver mutation-positive guideline. Based on that primer, what is new for first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: Even though I will say there is not a lot of new trial data that was incorporated into this guideline, there were some updates and just some meaningful long-term data that we incorporated. I think first and foremost, there is a new top-level recommendation in this guideline pertaining to molecular testing, which is absolutely critical in both the driver mutation-positive and driver mutation-negative space. I think we tend to think that, oh, well, molecular testing really only pertains to then finding a driver mutation. But the lack of a mutation is absolutely critical as well, right? Because that is what leads us down the mutation-negative pathway. We also need this molecular testing to assess PD-L1 status. We are seeing emerging data on molecular mutations that might confer resistance to certain immunotherapy-based strategies. So the committee felt strongly that a recommendation on molecular testing is critical to include in both the driver mutation-positive guideline and the driver mutation-negative guideline. I will also say that we are now seeing five and six-year updates from some of the landmark trials of immunotherapy in driver mutation-negative non-small cell lung cancer. It is really incredible to see that in some of these trials, we are seeing very impressive durability of the treatment in the patient subsets that we are commenting on. In others, perhaps that durability is less clear, and I think that leads to challenges in making a recommendation on any one particular regimen. And I think that is nowhere more clear than in the squamous subset. I think that was one perhaps subtle change that is in this guideline where, particularly in the PD-L1 negative squamous population, the committee felt that no one regimen really was worthy of standing above the others. Sometimes I think it is important to really champion one unique regimen if we feel that the data is there to support it. But I think it is equally important to list multiple regimens where the data is less clear. I think another point is that while perhaps there were no new regimens that we have added or that led to other clear changes in the prioritization of one regimen over another, there are other unique data subsets that I think come into play in making a decision and that really are important when looking at the discussion on any one recommendation from this guideline. For example, we know there is emerging data on perhaps the significance of molecular alterations in KEAP1 or STK11 and how that might influence frontline decision-making. You know, there is not a prospective phase III trial in this population, but I think we still need to use that data in certain scenarios to make recommendations for a particular patient. Another example of a trial that, again, did not change our recommendations, but I think one can incorporate in their decision making is the KEYNOTE-598 trial. Now, this is not a new study, but what it studied was pembrolizumab versus pembrolizumab plus ipilimumab in a PD-L1 high subset, and found that the addition of ipilimumab to pembrolizumab in the PD-L1 high population did not significantly improve clinical efficacy. And so while pembrolizumab plus ipilimumab is not an approved regimen, it is hard to extrapolate that to our combination treatments that are approved. I think some clinicians might find that data valuable when making a frontline treatment decision on a patient who has PD-L1 high status. So a bit of a whirlwind tour, but I think there are still multiple factors that went into this guideline that are important to review when making treatment decisions for any one patient. Brittany Harvey: Absolutely. I think what you just mentioned in having that upfront molecular testing is really key for individualized patient care. And the evidence summaries that you provide in addition to the recommendations are really important for clinicians to be able to refer to as they are making decisions in their clinic. So then beyond those changes for first-line therapy, what is updated for second-line and subsequent therapies? Dr. Joshua Reuss: For second-line and subsequent therapies, we did see one new treatment recommendation join these ranks, and that was telisotuzumab vedotin. Telisotuzumab vedotin, quite a mouthful. That is an antibody-drug conjugate. I like to think of that as smart chemotherapy, targeted chemotherapy, where you are trying to utilize some aspect of a marker that is selectively expressed or overexpressed on the cancer surface to then shepherd in the anticancer molecule, a highly potent chemotherapeutic in the case of currently approved antibody-drug conjugates, to exert antitumor killing effect. So in this case, the antibody-drug conjugate telisotuzumab vedotin targets MET overexpression. So telisotuzumab is an antibody targeting MET, and that is conjugated to an MMAE highly potent chemotherapeutic payload called vedotin. So we know MET can be selectively expressed and overexpressed in non-small cell lung cancer in both driver mutation-positive and mutation-negative subsets. The data that led to this approval was from the phase II LUMINOSITY trial which evaluated telisotuzumab vedotin, or Teliso-V, in many subsets. But the subset that really showed promise and was expanded was the EGFR wild-type, non-squamous, non-small cell lung cancer population with MET overexpression. And so in 78 patients with high levels of expression, the response rate here was 34.6%, median progression-free survival of 5.5 months, and a median overall survival of 14.6 months. With an overall acceptable safety profile; grade 3 or higher adverse events, neuropathy was perhaps the most common at 7%, also increased ALT at 3.5%, and pneumonitis at 2.9%. Now this was phase II data that led to an accelerated approval. There is an ongoing phase III study randomizing patients with high expression to Teliso-V versus docetaxel. That is the phase III TeliMET study. But it is nice that we now have another option for patients, perhaps a more biomarker-directed option with, again, this MET overexpression. And again, it further reinforces the importance of molecular testing in patients with traditionally driver mutation-negative non-small cell lung cancer, whether that is upfront or at progression, and in particular utilizing immunohistochemistry to assess MET expression in these patients. And this does join another ADC that we had previously made an update in our recommendation, which is trastuzumab deruxtecan, which is approved for those patients with HER2-overexpressing non-small cell lung cancer. So just again to reiterate the importance of molecular testing in patients both at the outset of their treatment and upon progression on frontline therapy. Brittany Harvey: Definitely. It is great to have this new antibody-drug conjugate join the treatment options, and as you mentioned, very important in this case to have that molecular testing done at the outset and at progression. So then in your view, what should clinicians know as they implement this living guideline, and how do these changes impact patients with non-small cell lung cancer? Dr. Joshua Reuss: Because there are so many different regimens that one can consider for any one patient, I think it is easy to become overwhelmed and stress on, "Am I making the right choice for my patient?" And I think one of the key take home points is that in many cases, there is no one right regimen. And I think one has to weigh several factors. It is the treatment schedule. It is the toxicity profile. It is the molecular profile of the patient. It is the patient preference. You know, there are so many factors here. And I would like to draw the reader and viewer's attention to an important section of these guidelines, particularly the Patient and Clinician Communication section, where we have a box focused on discussion points between patients and clinicians, which I think focuses on several of the high-level points that one can emphasize in making these decisions, ranging on things from: what are the goals of the treatment? What are the risks and benefits to any one approach? What are comorbidities that should be factored in? Common concerns, toxicity management, clinical trial consideration. All of these factors that I think are incredibly important in making that frontline treatment decision and implementing a regimen that both the clinician and, more importantly, the patient feels comfortable with. Brittany Harvey: It is really important that there is shared decision-making in these scenarios. And I think that patient-clinician communication section can tease out some of those preferences from the patient end and talk through the risks and benefits of different regimens as well. As we mentioned at the top of this episode, this guideline is a living guideline and updated on an ongoing basis. So what is the panel examining and keeping an eye on for future updates to this guideline? Dr. Joshua Reuss: So I think there are a lot of exciting new therapies and more up-to-date trials that we are anxiously awaiting the results of on our committee, and I think the oncology community in general is awaiting the results of. When we will have these results, I think, is a bit of an open-ended question, but I can give some insight on several of the trials that our committee is really keeping a close eye on. One that we have mentioned for several guideline iterations is the ECOG-ACRIN INSIGNA trial. This is a phase III clinical trial comparing pembrolizumab versus pembrolizumab plus carboplatin and pemetrexed chemotherapy in PD-L1 positive, non-squamous, non-small cell lung cancer. We talk about there being different regimens that can be considered in PD-L1 positive and PD-L1 high subsets, namely immunotherapy alone or immunotherapy plus chemotherapy, but there is no direct head-to-head comparison here. So this trial hopefully will answer that question. It has now finished accrual. There are other very interesting molecules and trials. I think another interesting compound is ivonescimab. This is a PD-1/VEGF bispecific antibody that is currently approved in China as monotherapy in patients with PD-L1 positive non-small cell lung cancer based off of the HARMONi-2 trial, where the progression-free survival of this bispecific antibody, ivonescimab, appeared superior to pembrolizumab. And we are looking closely at ongoing trials to see if these results will be replicated in an ex-China population. And if so, I think it could have a real impact and change on our guidelines. Still other very interesting things. There are obviously confirmatory studies for antibody-drug conjugates, such as the TeliMET study that I alluded to earlier, and many promising antibody-drug conjugates, both bispecific and trispecific antibody-drug conjugates, that hopefully can inform practice. And then there are several unique subsets of populations that I think we now are utilizing data on to make decisions, but a lot of that is retrospective in small subsets where we do not have that prospective data. And there are several trials ongoing in some of these subsets to try to gain clarity on what regimen may be the best for patients. One example is the phase III TRITON trial, which is looking at comparing CTLA-4 containing regimen, particularly the POSEIDON regimen of durvalumab plus tremelimumab and chemotherapy, versus the KEYNOTE-189 regimen, which is pembrolizumab plus carboplatin and pemetrexed, in patients with non-squamous, non-small cell lung cancer that have alterations in either KRAS, KEAP1, and/or STK11. There is a lot of both preclinical and clinical data to suggest that patients with these alterations in STK11 and KEAP1 may be more resistant to a PD-1 based treatment approach, and perhaps the incorporation of CTLA-4 can lead to a more meaningful response in this unique subset. Obviously, that data, it is retrospective, it is in small subsets. And when you add in a CTLA-4 molecule, you are also introducing greater risk for toxicity. So this trial is going to be very important in elucidating: is there a benefit in that unique subset? Does that data that we see retrospectively in this small subset hold true when evaluated in a prospective fashion? So while our guideline, our most recent comprehensive panel update, may not have had a lot of new data in it that has influenced frontline treatment decision-making, I think the future is bright and there are a lot of novel studies and novel treatments on the horizon that will hopefully improve the outcomes for our patients. Brittany Harvey: Absolutely. We will look forward to the results of those ongoing trials to provide more options and particularly clarity for patients with non-small cell lung cancer and to inform this guideline and its many updates to come. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Reuss. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Anfang 2026 haben die USA ihre Ernährungspyramide auf den Kopf gestellt: Protein und Fett oben, Brot und Getreide ganz unten. Die Empfehlung für Protein wurde von 0,8 auf 1,2–1,6 Gramm pro Kilogramm Körpergewicht fast verdoppelt. Butter und Vollfett-Milch sind plötzlich wieder erlaubt. Und das Motto lautet: „Eat Real Food.“Gleichzeitig kritisiert die Deutsche Gesellschaft für Ernährung diese Empfehlungen.Wer hat Recht? Und was bedeutet das für Dich?In dieser Folge erfährst Du, was die Wissenschaft tatsächlich über Protein, Fett und verarbeitete Lebensmittel sagt – jenseits von Schlagzeilen und Ideologie. Du bekommst konkrete Zahlen, eine einfache Faustregel für Deinen Proteinbedarf und drei simple Taktiken, die Du sofort umsetzen kannst. Egal, ob Du abnehmen, Muskeln erhalten oder einfach gesünder essen willst.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.Nur diese Woche: Sichere Dir Dein #DRNBLBR Gym Towell – solange vorrätig: drnblbr.de.____________Erwähnte Tools und Ressourcen:Johanna Bayer: quarkundso.deMichael Pollan: „In Defense of Food“ (Buch)Yazio Pro (Ernährungs-App)Mark Maslow: „Looking Good Naked – Die Gesamtausgabe“ (Südwest Verlag)Literatur:USDA/HHS (2025): Dietary Guidelines for Americans 2025-2030. realfood.govHelms E (2026): Beyond the Headlines: The 2025-2030 Dietary Guidelines for Americans, a MASS Perspective. MASS Research Review, Vol. 10, Issue 2.Snetselaar LG et al. (2021): Dietary Guidelines for Americans, 2020-2025: Understanding the Scientific Process, Guidelines, and Key Recommendations. Nutr Today, 56(6):287-295.de Jesus JM et al. (2024): Addressing misinformation about the Dietary Guidelines for Americans. Am J Clin Nutr, 119(5):1101-1110.Monteiro CA et al. (2018): The UN Decade of Nutrition, the NOVA food classification and the trouble with ultra-processing. Public Health Nutr, 21(1):5-17.Krebs-Smith SM et al. (2010): Americans do not meet federal dietary recommendations. J Nutr, 140(10):1832-1838.Pineda E et al. (2024): Food environment and obesity: a systematic review and meta-analysis. BMJ Nutr Prev Health, 7(1):204-211.Leydon CL et al. (2023): Aligning Environmental Sustainability, Health Outcomes, and Affordability in Diet Quality: A Systematic Review. Adv Nutr, 14(6):1270-1296.Herforth AW et al. (2020): Introducing a Suite of Low-Burden Diet Quality Indicators That Reflect Healthy Diet Patterns at Population Level. Curr Dev Nutr, 4(12):nzaa168.Pollan M (2008): In Defense of Food: An Eater's Manifesto. Penguin Press.____________Shownotes und Übersicht aller Folgen.Trag Dich in Marks Dranbleiber Newsletter ein.Entdecke Marks Bücher.Folge Mark auf Instagram, Facebook, Strava, LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

Fight Science is a special segment of the Conscious Combat Club podcast where we invite researchers to take a deep dive into a paper they've written and explain it to us as though we're 14 years old. In this episode I interview Molly Higgins (she/her), a doctoral candidate in clinical psychology with a clinical focus on trauma & PTSD, and a research focus on physical activity as an adjunct intervention for trauma-related disorders. In this episode we the guidelines: Trauma-Informed Guidelines For Interpersonal Violence Survivors in Combat Sports To contact Molly: Email: mhiggin3@uccs.edu Instagram: https://www.instagram.com/mollyhigg/?hl=en Read the guidelines here: https://osf.io/wc3e5/files/3zdsv To get involved with the Conscious Combat Club: - Donate: https://conscious-combat-club.raiselysite.com/ - Visit our site https://www.consciouscombat.club/ - Rounds 4 Respect: https://rounds4respect.org/ - Join the waitlist for Melbourne classes https://www.consciouscombat.club/naarm - Become a conscious combat coach https://www.consciouscombat.club/coaching - Join our mailing list "Mat Chat' https://www.consciouscombat.club/mat-chat SUPPORT LINKS: Some listeners might find parts of this conversation distressing. Please take care, link in your support networks, or refer to one of these organizations if you need: Eating disorder support: https://www.eatingdisorders.org.au/ Mental health support: https://www.beyondblue.org.au/get-support Domestic, family and sexual violence counselling, information and support https://www.1800respect.org.au/ Sexism in sport https://www.respectvictoria.vic.gov.au/ DirectLine (Alcohol & Drug Support) – 1800 888 236 (24/7) http://www.directline.org.au/ QLife (Queer-Specific Peer Support) – 1800 184 527 (3pm – midnight) - https://qlife.org.au/ Lifeline (Crisis Support & Suicide Prevention) – 13 11 14 (24/7) http://www.lifeline.org.au/gethelp Thank you so much to Nari for the beautiful song "Shape Me" heard at the beginning and end of this episode. Nari wrote this song about Shape Your Life, a boxing program for self-identified female survivors of violence in Canada. She wrote this song using the words and experiences shared by participants with Cathy Van Ingen. You can find out more about Shape Your Life in my interview with Cathy in Episode 8. You can hear more of Nari's work by going to her Instagram: @narithesaga

It is time to revisit Data Clean Rooms, having dedicated seven previous episodes to the topic across both the English and Spanish-language channels. The convergence of advanced data management techniques, more mature Privacy Enhancing Technologies, and sophisticated 1st-party data-based collaboration scenarios (on the back of AI, retail media, and Connected TV) already call for frequent updates. This is now accompanied by a more nuanced legal analysis that will benefit from the recent EDPS v. SRB (CJEU) case (on the relative nature of “personal data”).Some common, burning questions that you will find answered in this episode: How do you apply Joint Controllership agreements to the various stages in common business cases? How to handle more complex relationships involving two or more parties?References:* Jacob Feder on LinkedIn* Jacob Feder at Fieldfisher* Peter Craddock: EDPS v SRB, the relative nature of personal data, processors, transparency, impact on MarTech and AdTech (Masters of Privacy, September 2025)* Nicola Newitt (Infosum): the legal case for Data Clean Rooms (Masters of Privacy, March 2023)* Matthias Eigenmann (Decentriq): Confidential Computing, contractual relationships and legal bases for Data Clean Rooms (Masters of Privacy, March 2024)* Damien Desfontaines: Differential Privacy in Data Clean Rooms (Masters of Privacy, January 2024)* Guidelines 8/2020 on the targeting of social media users* Fashion ID GmbH & Co. KG v Verbraucherzentrale NRW (CJEU, 2019): The operator of a website that features a Facebook ‘Like' button can be a controller jointly with Facebook in respect of the collection and transmission to Facebook of the personal data of visitors to its website.* Digital Omnibus Regulation Proposal (EU Commission, November 19th 2025)* Meta Platforms Inc and Others v Bundeskartellamt (CJEU, 2023) This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mastersofprivacy.com/subscribe

Can you really "have it all"? Dr. Sharon Malone OB-GYN, New York Times bestselling author of Grown Woman Talk, and Chief Medical Advisor at Alloy Health joins me for an honest conversation about what it really takes to balance medicine, motherhood, and everything in between. Dr. Malone and I talk about the things we don't usually say out loud. How do you balance being a great doctor, a present parent, and a supportive partner when society tells you to excel at all three simultaneously? Dr. Malone practiced medicine before and after the Women's Health Initiative, so she has a unique perspective on how hormone therapy went from being standard care to being feared and how that fear disproportionately affected women of color. We discuss why only 1% of Black women who are eligible for hormone therapy are actually on it, despite suffering the longest and most severe menopausal symptoms.We also talk about her work with Alloy Health, her new podcast The Second Opinion, and why she believes menopause is inevitable but suffering is not. Plus, we get into the uncomfortable truth about medical racism, implicit bias, and why your gut feeling matters more than your doctor's ego.HighlightsGive yourself grace in midlife perimenopause decreases your coping threshold for everything you're already juggling.Women of color carry the weight of representing their entire group, not just themselves, which adds invisible pressure.Diversity in healthcare leadership literally changes what research gets funded and what treatments get offered.Only 1% of Black women eligible for hormone therapy are actually on it, despite having more severe and longer-lasting symptoms.The "adipose tissue theory" that Black women don't need hormones because they make more estrogen on their own is completely false.Racialized medicine affects everything from endometriosis diagnosis (only thin white women?) to pain management assumptions.If your doctor gets mad that you asked for a second opinion, you need a different doctor.Guidelines are guardrails, not laws medicine requires both confidence and humility.Dr. Malone's book Grown Woman Talk is everything you need to know about navigating midlife with confidence and information. And remember: trust your gut. If something feels off, keep advocating until someone listens.I have an incredible lineup of guests coming up, so make sure you subscribe and leave a review so you never miss episodes like this one!Links:Get in touch with Dr. Malone:WebsiteBookInstagramPodcastGet in Touch with Me: WebsiteInstagramYoutubeSubstackMentioned in this episode:GSM CollectiveThe GSM Collective - Chicago Boutique concierge gynecology practice Led by Dr. Sameena Rahman, specialist in sexual medicine & menopause Unrushed appointments in a beautiful, private setting Personalized care for women's health, hormones, and pelvic floor issues Multiple membership options...

President Trump's Board of Peace, pregnancy centers targeting phones, new federal alcohol guidelines, and a husband-and-wife folk duo. Plus, Cal Thomas on the immigration rhetoric in Minnesota, the meatiest race in motorsports, and the Thursday morning newsSupport The World and Everything in It today at wng.org/donateAdditional support comes from Dordt University's online Master of Education program- equipping students with knowledge and skills in their specialization. dordt.edu

In this episode, Dr. Thomas Hemingway explains the new U.S. Dietary Guidelines that were just released in January 2026 and what they mean to you.He will simplify the guidelines and explain the Protein-Forward approach and also dispel the common Protein Myths that have been out there for decades and share what the lates data shows and how you can Optimize your Nutrition and your Life so you can not only add Years to your life but Life to your Years.  Aloha and please share with a friend!Join my Free Masterclass on Midlife Hormones, "Why You Don't Feel like Yourself anymore and What to Do about it!"*ACCESS my FREE workshop, "GET 10 Years Younger, Stronger, and Sharper"  How to turn back your biological age 10-20 years so you can do the things you want to do that you no longer thought possible due to your age.  Perform at your best and live your best life!*And, in my new Performance, and Longevity medical practice we specialize in turning back your biological age and OPTIMIZING HORMONES so you can feel a decade or more younger so you can do the things you want to do that you thought were no longer possible due to your age.  Join the waitlist here!*SHARE with a Friend and please drop a Review:)*Don't wait to Prioritize your health, Start Today with the Simple and Powerful Steps detailed in my Best-selling book.*GET DIRECT ACCESS to DR. HEMINGWAY in these AMAZING COURSES!**Free resource: 'The truth about GLP-1s and their alternatives' - https://drthomashemingway.myflodesk.com/n1yyjkcb68Mahalo and Aloha andTo your health,

Do Native Americans need more encouragement to consume saturated fats? Native nutritionists are wondering how the new federal dietary guidelines just unveiled by U.S. Secretary of Health and Human Services Robert F. Kennedy, Jr. intersects with decades of scientific research urging the population with the highest rates of heart disease to limit their saturated fat intake. The new federal food pyramid shows up in recommendations for programs like Women, Infants, and Children (WIC), Head Start, Indian Health Service, and the National School Lunch Program. Tribes in the Pacific Northwest are stuck between a rock and a hard place when it comes to seals taking a bite out of the salmon populations they worked decades to preserve. The seals are protected by the Marine Mammal Protection Act. They feast on fish that on which the tribes rely. We will look at how this situation affects tribal treaty rights and what tribes are doing in response. A handful of organizations are working to strengthen traditional connections between urban Native residents and buffalo. Organizers in Chicago and Denver are among those working to put the animals closer to Native people who might not otherwise have exposure to a significant traditional source of food. GUESTS Dr. Tara Maudrie (Sault Ste. Marie Tribe of Chippewa Indians), assistant professor at the University of Michigan in the School of Social Work Cecilia Gobin (Tulalip), conservation policy analyst with the Northwest Indian Fisheries Commission Dnisa Oocumma (Eastern Band of Cherokee), community engagement coordinator for the American Indian Center Lewis TallBull (Cheyenne and Arapaho Tribes of Oklahoma), co-founder and president of Sacred Return Dr. Valarie Jernigan (Choctaw), professor of medicine and director of the Center for Indigenous Health Research and Policy at Oklahoma State University's Center for Health Sciences Carley Griffith-Hotvedt (Cherokee), executive director of the Indigenous Food and Agriculture Initiative

A combination of four shows over the last year, put together as a 9 hour series:Country Roads Take Me to the Hospital (3/13/25)One Nation Under God Over Prescribed (5/13/25)New Boss: Fatter than the Old Boss (7/17/25)Inverted Food Pyramid Scheme (1/8/26)*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.WEBSITEFREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVE-X / TWITTERFACEBOOKINSTAGRAMYOUTUBERUMBLE-BUY ME A COFFEECashApp: $rdgable PAYPAL: rdgable1991@gmail.comRyan's Books: https://thesecretteachings.info- EMAIL: rdgable@yahoo.com / rdgable1991@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

UGC Regulations Hearing in Supreme Court Today | UGC Guidelines उखाड़ फेकेंगे | Sanjay Dixit

Send Zorba a message!Dr. Zorba looks at new guidelines laid out by the World Health Organization regarding GLP-1 drugs. He helps a caller who has questions about which vitamins to take, and helps a emailer about how to regain their appetite. In our Quack Tales segment we hear about modern day blood letting, and we revisit the idea of prescribing Zorba's laugh for medicinal purposes.Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Join us for our next webinar: Focus on Guidelines. Panelists will discuss their approaches to a range of difficult cases in multiple areas, including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and vasculitis, and discuss how they apply the guidelines in everyday practice. You'll hear different perspectives and practical tips you can use in clinic. Panelists: Audrey Gibson, PA-C Benjamin A. Smith, PA-C Jack Cush, MD Following the discussion, join a live Q & A with the panelists. Register now to reserve your spot!  This is our second Tuesday Night Rheumatology this month as part of our Mission: APP Partners in Care campaign

Send Zorba a message!Dr. Zorba looks at new guidelines laid out by the World Health Organization regarding GLP-1 drugs. He helps a caller who has questions about which vitamins to take, and helps a emailer about how to regain their appetite. In our Quack Tales segment we hear about modern day blood letting, and we revisit the idea of prescribing Zorba's laugh for medicinal purposes.Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

How much protein should you eat? Guest Bio: Holli Ryan is a food and nutrition expert, registered and licensed dietitian-nutritionist, health and wellness writer, blogger, and senior digital marketing specialist. She graduated from Florida International University and is a member of the Academy of Nutrition and Dietetics. In her free time, she enjoys photography, travel, cooking, art, music, and nature.

In this episode, Dr. David Jockers dives into the benefits of the Protein Sparing Modified Fast, a powerful tool for burning fat, especially visceral fat. He explains how this strategy promotes fat loss while preserving lean muscle mass, even with a calorie-restricted diet.   Dr. Jockers shares how fasting triggers autophagy and the role it plays in cellular rejuvenation, helping the body break down old, damaged mitochondria and replace them with healthier ones.   He also discusses how protein-sparing fasting impacts insulin sensitivity, brain function, and overall resilience, while offering practical tips for implementing this approach into your lifestyle.   In This Episode:  00:00 Introduction to Fasting and Its Historical Context 00:48 Protein Sparing Modified Fast Explained 06:57 Dr. Jockers' Journey into Holistic Health 12:45 Introduction to Fasting Practices 14:20 Personal Fasting Experience and Benefits 17:32 Intermittent Fasting and Its Popularization 27:20 Autophagy and Cellular Rejuvenation 36:21 Challenges of Extended Fasting 37:13 Introduction to Protein Sparing Modified Fast 37:54 Benefits and Guidelines of Protein Sparing Modified Fast 40:35 Practical Tips for Protein Sparing Modified Fast 45:15 Addressing Common Concerns About Fasting 48:53 The Role of Ketones in Brain Health 54:42 Spiritual and Physical Benefits of Fasting 56:42 Autophagy and Protein Sparing Modified Fast 01:03:33 Tips for Enhancing Insulin Sensitivity 01:06:20 Favorite Meals and Desserts 01:08:31 Concluding Thoughts and Favorite Bible Verse   If you want practical, natural strategies to balance your hormones, heal your gut, boost your energy, and slow aging, don't miss The Dr. Josh Axe Show. Dr. Axe blends ancient wisdom with cutting-edge science and brings on world-class experts for unfiltered conversations you won't hear anywhere else. Transform your health from the inside out and subscribe to The Dr. Josh Axe Show, with new episodes every Monday and Thursday.   If you're looking to boost your health naturally, Paleo Valley's Super Greens powder is a game-changer. Packed with 23 organic superfoods, it provides all the nutrients your body needs for boundless energy and vitality, without the digestive issues that come with cereal grasses. For 15% off, visit paleovalley.com/jockers and use code JOCKERS at checkout.   When it comes to cooking, Chef Foundry offers the perfect solution with their P 600 ceramic cookware, which is free from Teflon, PFAS, and plastic coatings. Made with Swiss-engineered ceramic, this cookware makes it easy to prepare healthy meals without the toxins. Take 20% off with code SAFE20 at chefsfoundry.com/jockers and upgrade your kitchen today.     "Protein Sparing Modified Fast helps quench satiety, and most people on it don't feel as hungry or have cravings."      Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean TuneIn Radio   Resources: Visit paleovalley.com/jockers for 15% off with code JOCKERS. Visit chefsfoundry.com/jockers for 20% off with code SAFE20. Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https://www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/ 

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: UK looks at starting universal T1D screening, Dexcom's CEO mentions a new product, bariatric sugery vs GLP medications, FDA approves update to prescribing info for inhaled insulin, miscroplastic and diabetes link studied, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: (Stacey Track) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. We are less than one month from our first MNO of 2026. Please join us in Silver Spring MD Feb 20 and 21. It's going to be amazing. We're going to Nashville next March 6-7 and we're going to have a great event a Club 1921 we just added on Thursday March 5th for health care providers and patient leaders. All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX   All UK children could be offered screening for type 1 diabetes using a simple finger-prick blood test, say researchers who have been running a large study. This is the ELSA study - Early Surveillance for Autoimmune diabetes, a first of its kind UK study. They tested blood samples from 17,931 children aged 3-13 for autoantibodies, markers of type 1 diabetes that can appear years before symptoms. Families of children found to have early-stage type 1 diabetes received tailored education and ongoing support to prepare for the eventual onset of type 1 diabetes symptoms and to ensure insulin therapy can begin promptly when needed, reducing the chances of needing emergency treatment. Those with one autoantibody also received ongoing support and monitoring.   Some families were also offered teplizumab, the first ever immunotherapy for type 1 diabetes, which can delay the need for insulin by around three years in people with early-stage type 1 diabetes. The second phase has launched and will expand screening to all children in the UK aged 2-17 years, with a focus on younger children (2-3 years) and older teenagers (14-17 years). The research team aims to recruit 30,000 additional children across these new age groups. ELSA 2 will assess how screening can be scaled across the NHS and evaluate its cost-effectiveness. https://www.birmingham.ac.uk/news/2026/childhood-type-1-diabetes-screening-is-effective-and-could-prevent-thousands-of-emergency-diagnoses XX At the J.P. Morgan Healthcare Conference Dexcom CEO Jake Leach says they're going to launch a new product outside the US. I'll link up that interview, The full quote: "When you look at the outside the U.S., there are a lot of structures that are tiered. Patients have access to different types of products, so we've got a new one that we want to introduce that will add flexibility there. It's based on the G7 platform, just like Dexcom ONE+, but it has a unique experience that's tailored for a subset of users that, today, don't have access to Dexcom." Your guess is as good as mine, but sounds more like a pricing or ordering issue than a new bit of hardware or software. Dexcom will also bring Stelo to some international markets this year. And plans a new mobile app experience for the wearable biosensor meant for people who don't dose insulin. Leach also says G8 will be much smaller and with more capability. but is a few years away. https://www.drugdeliverybusiness.com/dexcom-ceo-jake-leach-2026-roadmap-jpm/ XX A new international consensus statement provides guidance for the use of diabetes technology during pregnancy for women with type 1 diabetes (T1D), type 2 diabetes (T2D), or gestational diabetes (GD).   Organized by the diaTribe Foundation, the document was based on evidence where available, as well as opinion from an international group of experts in endocrinology, diabetes technology, and obstetrics & gynecology, among others.   This is the first set of recommendations specifically addressing the use of diabetes technology in pregnancy – and we'll link it up. https://www.medscape.com/viewarticle/new-consensus-statement-addresses-diabetes-tech-pregnancy-2026a100020d XX Bariatric surgery beats GLP-1s for type 2 diabetes across income levels. This study was published this month, looking at nearly 300 patients are 4 medical centers. Success here is measured by lower blood glucose levels, higher weight loss (28% vs. 10%), less use of diabetes medications, remission of diabetes to the point of no longer needing to inject insulin, and reduced risk factors for cardiovascular disease.     Bariatric surgery was better than medical therapy across all social backgrounds, they found, and not just in areas of higher deprivation. The ancillary study was smaller, and some of the participants randomized in earlier stages crossed over from medical to surgical treatment, and the reverse. The authors acknowledged and accounted for these limitations, along with the rapid development of more powerful obesity drugs not fully captured in the study. This was a long term study – more than 12 years – and by the end of the study more people were choosing GLP1 medications. One dividing line: If someone hopes to lose 100 pounds, that's more likely with surgery than with medications.  "Ultimately, we need large, long-term, well-designed studies to clarify the best strategy for a given patient." https://www.statnews.com/2026/01/19/diabetes-study-bariatric-surgery-better-than-glp-1s/ XX Researchers at the University of California, Riverside have reported for the first time that a father's exposure to microplastics (MPs) can lead to metabolic problems in his children, including diabetes. This is a mouse study, but it looks at a previously unrecognized way in which environmental pollution may influence the health of future generations. MPs are extremely small plastic fragments, measuring less than 5 millimeters, that form as consumer products and industrial materials break down. Metabolic disorders describe a group of conditions that include elevated blood pressure, high blood sugar, and excess body fat, all of which raise the risk of heart disease and diabetes. The team found that female offspring of male mice exposed to MPs were far more prone to metabolic disorders than offspring of unexposed fathers, even though all offspring received the same high fat diet.     The research team hopes the findings will guide future investigation into how MPs and even smaller nanoplastics affect human development.   https://scitechdaily.com/microplastics-can-rewire-sperm-triggering-diabetes-in-the-next-generation/ XX The FDA has finalized four new recalls for certain lots of Abbott's FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to ongoing safety concerns. We told you about this in November when Abbott says some of its continuous glucose monitoring (CGM) sensors were providing incorrect low glucose warnings. Internal testing identified the issue—carbon building up in the sensors during the manufacturing process—and determined that approximately 3 million CGM sensors were affected. The sensors were distributed in the United States, Canada and several European countries.  When Abbott shared that announcement, the FDA was still reviewing the situation. No recalls had yet been finalized. Now, however, the agency has announced four new Class I recalls.   https://cardiovascularbusiness.com/topics/clinical/heart-health/fda-confirms-recalls-abbott-cgm-sensors-new-lawsuit-alleges-company-concealed-information XX   Insulet brings back it's U.S. Pod recycling program, now making it available to all U.S. customers. The Pod recycling program, offered at no cost to customers, enables users to request a recycling kit online. This allows them to return their used Omnipods. Insulet then decontaminates the returned Pods before transporting them to a company specializing in recycling for electronics and medical products. Insulet began recycling pilot programs in Mass and California and are rolling it out nationwide. Insulet also has "Pod takeback" programs outside the U.S. in several international markets. These programs enable customers to request a takeback kit by contacting their local customer support team.   https://www.drugdeliverybusiness.com/insulet-expands-us-pod-recycling-program/ XX Up next a new resource for a population at three times the risk for diabetes, but without a lot of access to health information. I The first diabetes information website primarily in ASL has launched. The site includes GIFs and videos on diabetes management and an ASL glossary of diabetes-related terms. This is from University of Utah Health – Called Deaf Diabetes Can Together. Deaf and hard of hearing people are at three times higher risk for diabetes, but access to health information in ASL is limited. https://healthcare.utah.edu/newsroom/news/2026/01/first-diabetes-information-website-asl-launches XX Novo Nordisk ended all work on cell therapies, including a Type 1 diabetes program, in October – and now has found a buyer. Aspect has acquired rights to the assets and giving Novo an option to reengage for later-stage development and commercialization. Novo is helping bankroll Aspect's development of the assets, investing in the company and providing research funding. The arrangement gives Novo a chance to profit from the programs down the line. Novo is eligible for royalties and milestone payments on future product sales and, having handed the reins to Aspect for now, can expand its role in later-stage development and commercialization. The integration will involve the transfer of capabilities and expertise from Novo sites in Denmark and the U.S. to Aspect's Canadian operations. https://www.fiercebiotech.com/biotech/novo-nordisk-offloads-diabetes-assets-aspect-amid-cell-therapy-retreat XX XX Lucas Escobar has carved a role by proving that healthcare marketing can be culturally resonant, commercially powerful and deeply human. As director and head of U.S. consumer marketing at Insulet, he has redefined how the Omnipod tubeless insulin pump shows up in culture, transforming a medical device into a symbol of identity, inclusion and empowerment.   Under Escobar's leadership, Insulet launched three breakthrough initiatives: Dyasonic: Sound of Strength, a Marvel comic collaboration introducing a superhero who uses Omnipod; The Pod Drop, which turned the sound of a pod change into a celebratory music track; and Omnipod Mango x Pantone, medtech's first color partnership, honoring the vibrancy of the diabetes community. Each blended creativity with purpose while driving results, helping fuel Omnipod's consistent double-digit growth and its position as the most prescribed insulin pump in the U.S.   Living with type 1 diabetes himself, Escobar brings lived experience to his work, using storytelling not just to sell, but to make people feel seen.   Click here to return to the 2026 MM+M 40 Under 40 homepage.   From the January 01, 2026 Issue of MM+M - Medical Marketing and Media https://www.mmm-online.com/40-under-40/40-under-40-lucas-escobar-insulet/ -- FDA approves an update to the prescribing info for Afrezza inhaled insulin. This is a revision to the recommendations for the starting mealtime dosage when patients switch from shots or insulin pumps. This is aimed at healthcare providers - the updated labeling was supported by results from the INHALE-3 trial. The FDA is still considering approval of Afrezza for kids – a decision there expect by summer. https://www.globenewswire.com/news-release/2026/01/26/3225442/29517/en/MannKind-Announces-FDA-Approval-of-Updated-Afrezza-Label-Providing-Starting-Dose-Guidance-when-Switching-from-Multiple-Daily-Injections-MDI-or-Insulin-Pump-Mealtime-Therapy.html   -- UK researchers have developed a calculator to predict whether someone is at risk for type 1 diabetes. They're hoping this helps in screening and in preventing DKA at diagnosis. They used the TEDDY study to create this calculator, which right now is in beta form and only for kids and teens ages 8-18. The current beta form of the calculator asks users to answer questions about four factors necessary to estimate a child's risk of developing type 1 diabetes: age, family history, number of confirmed autoantibodies, and genetic risk score. The calculator has been given regulatory approval as a diagnostic in the U.K., and he's working with a company that's hoping to bring it to the U.S. in the next few months in the form of a home genetic test kit. https://www.healthcentral.com/news/type-1-diabetes/new-calculator-might-help-predict-type-1-diabetes-before-symptoms-appear

On this week’s episode, we’re continuing our Guidelines Series exploring the 2022 ESC/ERS Guidelines for the diagnosis and treatment of Pulmonary Hypertension. If you missed our first episode in the series, give it a listen to hear about the most recent recommendations regarding Pulmonary Hypertension definitions, screening, and diagnostics. Today, we’re talking about the next steps after diagnosis. Specifically, we’ll be discussing risk stratification, establishing treatment goals, and metrics for re-evaluation. We’ll additionally introduce the mainstays of pharmacologic therapy for Pulmonary Hypertension. Meet Our Co-Hosts Rupali Sood  grew up in Las Vegas, Nevada and made her way over to Baltimore for medical school at Johns Hopkins. She then completed her internal medicine residency training at Massachusetts General Hospital before returning back to Johns Hopkins, where she is currently a pulmonary and critical care medicine fellow. Rupali’s interests include interstitial lung disease, particularly as related to oncologic drugs, and bedside medical education. Tom Di Vitantonio  is originally from New Jersey and attended medical school at Rutgers, New Jersey Medical School in Newark. He then completed his internal medicine residency at Weill Cornell, where he also served as a chief resident. He currently is a pulmonary and critical care medicine fellow at Johns Hopkins, and he’s passionate about caring for critically ill patients, how we approach the management of pulmonary embolism, and also about medical education of trainees to help them be more confident and patient centered. Key Learning Points 1) Episode Roadmap How to set treatment goals, assess symptom burden, and risk-stratify patients with suspected/confirmed pulmonary arterial hypertension (PAH). What tools to use to re-evaluate patients on treatment Intro to major PAH medication classes and how they map to pathways. 2) Case-based diagnostic reasoning Patient: 37-year-old woman with exertional dyspnea, mild edema, abnormal echo, telangiectasias + epistaxis → raises suspicion for HHT (hereditary hemorrhagic telangiectasia) and/or early connective tissue disease. Key reasoning move: start broad (Groups 2–5) and narrow using history/exam/testing. In a young patient without obvious left heart or lung disease, think more about Group 1 PAH (idiopathic/heritable/associated). HHT teaching point: HHT can cause PH in more than one way: More common: high-output PH from AVMs (often hepatic/pulmonary) Rare (1–2% mentioned): true PAH phenotype (vascular remodeling; associated with ALK1 in some patients), behaving like Group 1 PAH. 3) Functional class assessment WHO Functional Class: Class I: no symptoms with ordinary activity, only with exertion Class II: symptoms with ordinary activity Class III: symptoms with less-than-ordinary activity (can't do usual chores/shopping without dyspnea) Class IV: symptoms at rest Practical bedside tip they give: Ask if the patient can walk at their own pace or keep up with a similar-age peer/partner. If not, think Class II (or worse). 4) Risk stratification at diagnosis: why, how, and which tools Big principle: treatment choices are driven by risk, and the goal is to move patients to low-risk quickly. ESC/ERS approach at diagnosis (as described): Use a 3-strata model predicting 1-year mortality: Low: 20% ESC/ERS risk assessment variables (10 domains discussed): Clinical progression, signs of right heart failure, syncope WHO FC Biomarkers (NT-proBNP) Exercise capacity (6MWD) Hemodynamics Imaging (echo; sometimes cardiac MRI) CPET (peak VO₂; VE/VCO₂ slope) They note: even if you don't have everything, the calculator can still be useful with ≥3 variables. REVEAL 2.0: Builds on similar core variables but adds further patient context (demographics, renal function, BP, DLCO, etc.) Case result: both tools put her in intermediate risk (ESC/ERS ~1.6; REVEAL 2.0 score 8), underscoring that mild symptoms can still equal meaningful mortality risk. 5) Treatment goals and follow-up philosophy What they explicitly prioritize: Help patients feel better, live longer, and stay out of the hospital Use risk tools to communicate prognosis and to track improvement Reassess frequently (they mention ~every 3 months early on) until low risk is achieved “Time-to-low-risk” is an important treatment goal Also emphasized: The diagnosis is psychologically heavy; patients need clear counseling, reassurance about the plan, and connection to support groups. 6) Medication classes for the treatment of PAH Nitric oxide–cGMP pathway PDE5 inhibitors: sildenafil, tadalafil Soluble guanylate cyclase stimulator: riociguat Important safety point: don't combine PDE5 inhibitors with riociguat (risk of significant hypotension/hemodynamic effects) Endothelin receptor antagonists (ERAs) “-sentan” drugs: bosentan (less used due to side effects/interactions), ambrisentan, macitentan Teratogenicity emphasized Hepatotoxicity that requires LFT monitoring Can cause fluid retention and peripheral edema Prostacyclin pathway Prostacyclin analogs/agonists: Epoprostenol (potent; short half-life; IV administration) Treprostinil (IV/SubQ/oral/inhaled options) Selexipag (oral prostacyclin receptor agonist) 7) Sotatercept (post-guidelines) They note sotatercept wasn't in 2022 ESC/ERS but is now “a game changer” in practice: Mechanism: ligand trap affecting TGF-β signaling / remodeling biology Positioned as potentially more disease-modifying than pure vasodilators Still evolving: where to place it earlier vs later in regimens is an active question in the field 8) How risk category maps to initial treatment intensity General approach they outline: High risk at diagnosis: parenteral prostacyclin (IV/SubQ) strongly favored, often aggressive early Intermediate risk: at least dual oral therapy (typically PDE5i + ERA); escalate if not achieving low risk Low risk: at least one oral agent; many still use dual oral depending on etiology/trajectory For the case: intermediate-risk → start dual oral therapy (they mention tadalafil + ambrisentan as a typical choice), reassess in ~3 months; add a third agent (e.g., selexipag/prostacyclin pathway) if not low risk.  References and Further Reading Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. Erratum in: Eur Heart J. 2023 Apr 17;44(15):1312. doi: 10.1093/eurheartj/ehad005. PMID: 36017548. Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th World Symposium on Pulmonary Hypertension: what’s old is new. F1000Res. 2019 Jun 19;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. PMID: 31249672; PMCID: PMC6584967. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc. 2023 Apr 18;12(8):e029024. doi: 10.1161/JAHA.122.029024. Epub 2023 Apr 7. PMID: 37026538; PMCID: PMC10227272. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. PMID: 36877098. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. Erratum in: JAMA. 2022 Sep 6;328(9):892. doi: 10.1001/jama.2022.13696. PMID: 35412560.

439. Guidelines: Who's leading you? by StriveNinspire

Today, we dive into one of the most critical topics in chiropractic care: the real-world effectiveness of strategies for implementing guideline-concordant care for low back pain. We'll explore recent research that asks a simple but powerful question—do strategies designed to promote best practices in low back pain management actually change provider behavior?Research: Effectiveness of strategies for implementing guideline-concordant care in low back pain: a systematic review and meta-analysis of randomised controlled trialsSpecial Offers for Listeners: Learn more about Diabetes Reversal Group and become a licenseeSave $500 and Get a Free Cart- Learn more at Shockwave Center of America Today!Leander Tables- Save $1,000 on the Series 950 Table using the code EBC2025 — their most advanced flexion-distraction tableNovoPulse OA Recovery Program- learn more herePatient Pilot by The Smart Chiropractor is the fastest, easiest to generate weekly patient reactivations on autopilot…without spending any money on advertising. Click here to schedule a call with our team.Our members use research to GROW their practice. Are you interested in increasing your referrals? Discover the best chiropractic marketing you aren't currently using right here!

January is tough, but February can be a surprisingly powerful reset if you know how to use it. In this episode, we share why this month often feels draining, how hidden energy leaks show up across your day, and how a simple February energy audit can help you make small, strategic shifts that protect your time and capacity. Our goal is to help you stop drifting through February and start using it to refill your tank before the rest of the year ramps up.Prefer to read? Grab the episode transcript and resources in the show notes here: https://www.secondstorywindow.net/podcast/february-teacher-energy-tips/Resources:February Teacher Survival KitJoin the Teacher Approved Club!BlueAir humidifierHinge toppersConnect with us on Instagram @2ndstorywindow.Shop our teacher-approved resources.Join our Facebook group, Teacher ApprovedLeave a review on Apple Podcasts.Leave a comment or rating on Spotify.Related Episodes to Enjoy:Episode 48. How to Make Classroom Transitions Simple with Clear Beginnings and EndingsEpisode 49. Rapid Classroom Transitions: How to Save 45 Hours a YearEpisode 50. 3 Guidelines to Make Classroom Transitions Work Smarter Not HarderEpisode 161, How to Get Students Actively Engaged: 5 Teacher Approved Techniques

In this episode of the Lupus Foundation of America's The Expert Series podcast, Dr. Cindy Aranow discusses the newly released American College of Rheumatology treatment guidelines for systemic lupus erythematosus (SLE). She explains the importance of these guidelines in providing evidence-based recommendations for individualized patient care, the process of developing and updating the guidelines and key changes that emphasize optimal disease control and reducing long-term steroid use. Dr. Aranow highlights the need for patient engagement and communication with health care providers to ensure effective management of lupus.This episode of The Expert Series was sponsored by AstraZeneca. The Lupus Foundation of America would like to thank AstraZeneca for their support of education programs for people with lupus.Sign up to receive emails from the Lupus Foundation of America (LFA) when new episodes are published: https://support.lupus.org/site/SPageNavigator/email_subscribe_expert_series.htmlEpisode Takeaways:Treatment guidelines are recommendations, not mandates, and support - not replace - your doctor's clinical judgment.Lupus is a highly individualized disease, so care must be tailored to each person.A diverse group of experts develops and regularly updates guidelines based on new research.Guidelines help clinicians navigate complex and evolving medical evidence.Recent guidelines emphasize achieving remission or low disease activity while reducing long-term steroid use.Open communication and active patient involvement are essential for effective treatment decisions. Related Resources:Ask a Lupus Health Educator (LFA): https://www.lupus.org/care-support/ask-a-health-educatorFind Support Near You (LFA): https://www.lupus.org/resources/find-support-near-youNational Resource Center on Lupus (LFA): https://www.lupus.org/resourcesThe Expert Series (LFA): https://www.lupus.org/resources/lupus-the-expert-seriesNew Lupus Treatment Guidelines (ACR): https://rheumatology.org/press-releases/new-lupus-sle-clinical-practice-guidelines-released

How much protein should you eat? The new 2025-2030 Dietary Guidelines for Americans are shaking up the nutrition landscape! In this episode of Live Foreverish, Dr. Crystal sits down with registered dietitian, Holli Ryan, to discuss major updates, including the return of full-fat dairy and increased protein recommendations. The conversation also explores challenges in implementing these changes at home and in schools, conflicting messages about fat, and the removal of specific alcohol limits. #LELEARN #EDULFsocial Guest Bio: Holli Ryan is a food and nutrition expert, registered and licensed dietitian-nutritionist, health and wellness writer, blogger, and senior digital marketing specialist. She graduated from Florida International University and is a member of the Academy of Nutrition and Dietetics. In her free time, she enjoys photography, travel, cooking, art, music, and nature.

In this episode of the Alopecia Angel Podcast, we kick off 2026 by taking a critical look at the newly updated USDA food guidelines and what they really mean for your health and hair. While the shift toward prioritizing whole foods over processed foods is a step in the right direction, we'll break down why government guidelines are still just that: GENERAL. If you've tried “all the right things” and still feel stuck, this episode will help you understand why personalization (not trends or boxed diets) is the real piece you're missing. Healing, hair growth, and long-term health don't come from following rules blindly; they come from learning to question, understand, and support your body as an individual-PDF about medications that cause hair loss:https://alo-angel.mykajabi.com/opt-in-page-for-free-downloads-HELP IS WITHIN YOUR REACH!Alopecia Angel is dedicated to those seeking a holistic, natural, and safe approach to healing Alopecia from the inside out! The main force behind Alopecia Angel is a deep desire to help individuals achieve what I achieved with a natural treatment option, a well-rounded approach to health, wellness, and reversing Alopecia naturally without antibiotics, pharmaceuticals, cortisone shots to the head, or embarrassing creams.After seeing results with my multi-tiered natural Alopecia treatment, targeting mind, body, nutrition, environment, and other elements, I decided I wanted to share my findings and let others know that a natural, safe, and holistic method does in fact exist to regrow hair from alopecia. -Website: https://www.alopeciaangel.comYouTube Channel: https://www.youtube.com/alopeciaangelFacebook: https://www.facebook.com/alopeciaangelInstagram: http://instagram.com/alopecia_angel

Nishikant Dubey Countered by Sanjay Dixit on UGC Guidelines | BJP  IT Cell Split Down the Middle

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Benjamin Tolchin, MD, MS, FAAN, joins the podcast to provide clinical perspective on the recently published American Academy of Neurology (AAN) guidelines on functional seizures, drawing on his role as a contributing author to the recommendations. Tolchin, Director of the Center for Clinical Ethics at Yale New Haven Health and Associate Professor of Neurology at Yale School of Medicine, discusses what prompted the development of the first AAN guideline in this space and how the evidence base evolved to support formal recommendations. The conversation explores key considerations around diagnosing functional seizures, including history, semiology, EEG use, and the growing role of video documentation. Tolchin also addresses how clinicians should approach psychiatric comorbidities and co-occurring epilepsy, the evidence supporting psychological interventions, why pharmacologic therapies are not recommended for functional seizures themselves, and where major gaps remain in research to advance care in the years ahead.Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.Episode Breakdown: 1:10 – Why growing evidence prompted the first AAN guideline on functional seizures 3:20 – Diagnostic priorities including history, semiology, EEG, and video documentation 6:15 – Assessing psychiatric comorbidities and co-occurring epilepsy in functional seizures 9:15 – Neurology News Minute 11:30 – Evidence supporting psychotherapy for functional seizures 14:50 – Pharmacological evidence and use of antiseizure medications for functional seizures 18:35 – Barriers to advancing clinical trials in functional seizures 22:05 – Research priorities to refine treatment and long-term outcomes The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

In this episode, we review the clinical presentation, diagnosis, and treatment of uncomplicated urinary tract infections. Key Concepts Uncomplicated urinary tract infections (UTI) are defined as an infection localized to the bladder without any systemic signs or symptoms of infection in someone who is not immunocompromised, pregnant, catheterized, and has normal urologic anatomy. UTIs are most commonly seen in younger women. E. coli is by far the most common urinary pathogen. Symptoms alone drive most of the diagnosis of UTI; however, urinalysis and urine culture can be helpful in some circumstances. Nitrofurantoin (Macrobid) is recommended for men and women for first-line therapy in most patients. Fosfomycin, Bactrim, pivmecillinam, and certain B-lactams can be considered in certain circumstances. Women are usually treated for 3-5 days and men 5-7 days. Some evidence suggests inferior clinical outcomes for B-lactam; however, the amount of data in general is lacking for B-lactams. Recommended B-lactams (aside from pivmecillinam) include amoxicillin/clavulanate, cephalexin, cefadroxil, cefpodoxime, and cefdinir. References Nelson Z, Aslan AT, Beahm NP, et al. Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults: A WikiGuidelines Group Consensus Statement. JAMA Netw Open. 2024;7(11):e2444495. Published 2024 Nov 4. doi:10.1001/jamanetworkopen.2024.44495 Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257 Kurotschka PK, Gágyor I, Ebell MH. Acute Uncomplicated UTIs in Adults: Rapid Evidence Review. Am Fam Physician. 2024;109(2):167-174. https://www.wikiguidelines.org/

When the U.S. government released the new 2025–2030 Dietary Guidelines for Americans, most people probably didn't notice what didn't make headlines. But something important changed. For the first time in decades, the federal government removed specific drinking limits from its alcohol guidance. Gone was the already-weak recommendation of no more than one drink per day for women. Also missing? Any clear warning about alcohol's well-established link to cancer. What replaced it was vague language encouraging people to “drink less.” That might sound harmless. Reasonable, even. But when you look closely at the science—and the political and economic forces surrounding alcohol—this shift isn't neutral. It's dangerous. And it represents a clear retreat from evidence-based public health guidance at a time when alcohol-related harm in the U.S. is rising. In this episode, I'm taking a position:The new U.S. alcohol guidelines caved to Big Alcohol—and the consequences matter. For the full show notes, kindly go to this podcast episode link: https://hellosomedaycoaching.com/the-new-u-s-alcohol-guidelines-caved-to-big-alcohol-and-why-thats-dangerous/ 4 Ways I Can Support You In Drinking Less + Living More Join The Sobriety Starter Kit, the only sober coaching course designed specifically for busy women. My proven, step-by-step sober coaching program will teach you exactly how to stop drinking  — and how to make it the best decision of your life. Save your seat in my FREE MASTERCLASS, 5 Secrets To Successfully Take a Break From Drinking  Grab the Free 30-Day Guide To Quitting Drinking, 30 Tips For Your First Month Alcohol-Free. Connect with me for free sober coaching tips, updates + videos on YouTube, Instagram, Facebook, Pinterest and TikTok @hellosomedaysober. Love The Podcast and Want To Say Thanks? ☕ Buy me a coffee! In the true spirit of Seattle, coffee is my love language. So if you want to support the hours that go into creating this show each week, click this link to buy me a coffee and I'll run to the nearest Starbucks + lift a Venti Almond Milk Latte and toast to you! https://www.buymeacoffee.com/hellosomeday 

In this episode of Iron Culture, Eric Helms and Eric Trexler discuss the recent changes to the Dietary Guidelines for Americans (DGAs) and the implications of these updates. They begin by addressing the shift in their podcast schedule, emphasizing the importance of mental health and balance in their work. The conversation then transitions into a detailed analysis of the new dietary guidelines, highlighting the complexities of the process behind their formulation. Helms critiques the influence of corporate interests and the political landscape on the DGAs, while also acknowledging the positive aspects of the new recommendations, particularly the increased emphasis on protein intake. The hosts explore the historical context of dietary guidelines, the evolution of public health messaging, and the challenges of effectively communicating nutritional advice to the public. In this episode, Eric Helms and MASS Research delve into the complexities of the latest Dietary Guidelines for Americans (DGAs), discussing the implications of the visual representation of food groups and the recommendations for protein, fats, and processed foods. They critique the new guidelines for their lack of clarity and potential confusion, particularly regarding the emphasis on whole foods versus processed foods. The conversation highlights the disconnect between the written guidelines and their visual representation, which may mislead the public about healthy eating patterns. They also explore the political influences on these guidelines and how they may affect vulnerable populations, particularly in school lunch programs and social assistance programs. If you're in the market for some lifting gear or apparel, be sure to check out EliteFTS.com (and use our code "MRR10" for a 10% discount) Chapters 00:00 Introduction and Schedule Changes 07:15 The Dietary Guidelines Controversy 20:56 Understanding the Formation of Dietary Guidelines 32:30 The Influence of Food Industries on Guidelines 33:38 The Role of the Second Committee 43:49 Changes in Protein Recommendations 44:19 The Inverted Pyramid and Dietary Miscommunication 59:55 Understanding Fats in the New Guidelines 01:09:17 The Role of Full-Fat Dairy in Heart Health 01:15:06 Alcohol Consumption: New Guidelines Explained 01:21:52 Processed Foods and Public Health Implications 01:25:03 The Impact of Dietary Guidelines on Vulnerable Populations 01:30:34 Conclusions and Future Directions in Nutrition Guidelines

When you're preparing for NP boards, screening guidelines can seem a little dry, but these recommendations show up consistently on exams and form the foundation of primary care practice.   In this episode, Courtney and I run through an overview of the adult screening recommendations you'll need to know for primary care NP boards, leaning heavily on USPSTF recommendations.   Discover how to think through screening questions without getting lost in the nitty gritty detail.   Get full show notes, transcript, and more information here: https://blog.npreviews.com/primary-care-screening-guidelines-pass-np-boards   Follow us on Instagram: instagram.com/smnpreviewsofficial        

On this episode of Vitality Radio, Jared introduces a new series: The Vitality Verdict: Beyond the Headlines—designed to cut through the noise (and the politics) of natural health news and give you a clear, evidence-based perspective you can actually use. Using the newly released 2025–2030 Dietary Guidelines as the first case study, Jared breaks down what changed and why it matters for real life—especially for school lunches, WIC, and other programs that shape how millions of Americans eat. He also examines conflicts of interest on both sides of the debate and delivers his bottom-line Vitality Verdict on what this shift means for your health choices going forward.Products:Vitality Radio POW! Product of the Week: ZHOU Creatine Gummies BUY ONE GET ONE FREE! A $34.99 value! PROMO CODE: POW24Additional Information:RealMilk.comThe Westin A. Price FoundationVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

On episode #98 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 1/1/26 – 1/14/26. Host: Daniel Griffin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Rhinovirus-Associated Lower Respiratory Tract Infection in Hospitalized Adult Patients: A Retrospective Cohort Study (JID) Demise of the Milwaukee Protocol for Rabies (CID) Reply to Willoughby on Demise of the Milwaukee Protocol for Rabies (CID) Bacterial Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods (CID) Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke clinical criteria for infective endocarditis: Impact of excluding fever and updating diagnostic definition (CID) The diagnostic accuracy of procalcitonin for community-acquired bacteremia: an updated systematic review and meta-analysis (CMI: Clincal Microbiology and Infection) Noninferiority of One HPV Vaccine Dose to TwoDoses (NEJM) About the wastewater program (Colorado: Department of Public & Environment) Notes from the Field: Wastewater Surveillance for Measles Virus During a Measles Outbreak — Colorado, August 2025 (CDC: MMWR) Notes from the Field: Retrospective Analysis of Wild-Type Measles Virus in Wastewater During a Measles Outbreak — Oregon, March 24–September 22, 2024 (CDC:MMWR) Fungal The Last of US Season 2 (YouTube) Candidozyma auris (formerly Candida auris): Resistant, long-lasting, and everywhere (CMI: Clincal Microbiology and Infection) Long-range air dispersal as an important source of environmental contamination in Candida auris clustering: possible infection control implication (Infection Control & Hospital Epidemiology) Parasitic Dermlite Dermatoscopes (dermatoscopes.com) Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trials (BMJ) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Welcome to the Civilian Medical Podcast episode 081       Opening: “You never know when you'll be the First Responder” Core framing Most cardiac arrest victims are not found by EMS. They are found by bystanders. “The first five minutes are up to the bystander, and that determines survival”     Why the Guidelines Changed Key point The American Heart Association didn't change CPR because civilians were doing it wrong— they changed it because stress breaks memory. 2020 vs 2025 framing 2020: Correct, but cognitively complex 2025: Correct and easier to recall under pressure “In emergencies, complexity kills time—and time kills.” When you learn CPR, you are not learning it to save a stranger; it's most likely to be a family member.       The Big Shift: One Model for Every Emergency Chain of Survival 2020 Different chains depending on age and setting 2025 One chain. Every person. Every place. “If you remember one thing: recognize → compress → shock.”     Choking: What changed 2020 Abdominal thrusts emphasized Back blows inconsistently taught for adults 2025 Adults & children: 5 back blows → 5 abdominal thrusts Infants: 5 back blows → 5 chest thrusts Why EMS cares Rhythm matters under stress. “Think of it like CPR for choking—structured, repeatable, automatic.”     Opioid Overdose 2020 Naloxone discussed, but not central 2025 Naloxone clearly included without replacing CPR Key teaching Naloxone does not restart a stopped heart. CPR and AED always come first. Soundbites “Naloxone wakes breathing—not circulation.” “Narcan doesn't buy you out of CPR.”       What EMS Hopes You'll Stop Overthinking CPR Quality Unchanged science Push hard Push fast Don't stop unless you must 2025 emphasis Start early > start perfect “You cannot make them more dead.”     Dispatcher CPR: The Invisible Teammate Why this matters Dispatchers now teach off the same simplified framework Civilians who know the 2025 model cooperate faster “The guidelines were written with the idea that the dispatcher is on speakerphone.”     What This Means for You (Practical Takeaways) Actionable conclusions You don't need to be a healthcare provider to do CPR You need the right equipment and the right training What training is Dietrich doing in his community? “Confidence saves more lives than certification.” “You don't rise to the occasion—you fall to your level of preparation.” Final line “If EMS could speak to every bystander before an emergency, this is what we'd say: You already know enough to save a life; do CPR.”     Medical Gear Outfitters Use Code CIVILIANMEDICAL for 10% off    Skinny Medic - @SkinnyMedic | @skinny_medic | Medical Gear Outfitters   Bobby - @rstantontx | @bobby_wales   

Welcome to the Civilian Medical Podcast episode 081       Opening: “You never know when you'll be the First Responder” Core framing Most cardiac arrest victims are not found by EMS. They are found by bystanders. “The first five minutes are up to the bystander, and that determines survival”     Why the Guidelines […]

What actually counts as a whole food — and why does that matter when it comes to sugar?In this episode, I unpack the difference between foods with added sugars and whole foods that naturally contain sugar, like fruit and dairy. I talk about what “minimally processed” really means, why "food products" that contain forms of added sugars have quietly become part of everyday eating...and how all of this affects cravings, blood sugar, and our general health.I also give my own opinion on the latest US nutrition guidelines that were published in January 2026. I'm not a nutrition expert, but in this episode I share what I've experienced over the last 10 years eating whole foods that don't contain added sugars.To get personalized guidance to stop emotional eating and break free from cravings, plus support and accountability... apply here to join the 90-day program, Freedom from Cravings Formula TODAY.Do the Cravings Quiz and take the first step to get rid of your cravings! Struggling with cravings? Download your 5 tips HERE to discover how you can get rid of cravings... even when you feel tired or stressed.To rate and review this podcast: scroll down in your podcast player on your phone and click on the stars. To leave a review, scroll down a little more and click on "Write a Review". Once you've finished, select “Send” or “Save” in the top-right corner. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed on your review. After selecting a nickname, tap OK. Your review may not be immediately visible, but it should be posted soon. Thank you! - NettaDisclaimer: Information provided by Life After Sugar is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. This is general information for educational purposes only. The information provided is not a substitute for medical or professional care. Life After Sugar is not liable or responsible for any advice, information, services or product you obtain through Life After Sugar. You should always seek...

As seen on Gutfeld! Its the end of the week and Greg brings out the leftovers! Learn more about your ad choices. Visit podcastchoices.com/adchoices